Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades VistaGen Therapeutics to Hold

Maxim Group Downgrades VistaGen Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Buy to Hold.

byBenzinga Newsdesk

July 26, 2022

1 minute read

Maxim Group analyst Jason McCarthy downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Buy to Hold.

Glatfelter Suspends Dividend As Part Of Capital Allocation Reprioritization

By Bill Haddad

September 21, 6:51 AM

Glatfelter Corporation ("Glatfelter" or "the Company") (NYSE:GLT), a leading global supplier of engineered materials, today announced that the Board of Directors has suspended the Company's

GLT

Michigan Beats California In Legal Cannabis Sales: Why Is Golden State’s Weed Industry Losing Its Shine?

By Patricio Liddle

June 6, 10:16 AM

Michigan surpasses California in legal cannabis sales. High taxes and weak enforcement hurt California's market, while Michigan's thrives.

GHBWF

HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

By Benzinga Newsdesk

July 8, 6:07 AM

HC Wainwright & Co. analyst Yi Chen downgrades Meridian Bioscience (NASDAQ:VIVO) from Buy to Neutral and raises the price target from $30 to $34.

VIVO

News

Here’s Why Rivian (RIVN) Stock Is Rising

By Henry Khederian

May 10, 10:15 AM

Rivian Automotive Inc (NASDAQ: RIVN) shares are trading higher by 10.46% to $15.31 Wednesday morning after the company reported better-than-expected first-quarter results.

RIVN

Maxim Group Downgrades VistaGen Therapeutics to Hold

Related Posts

Glatfelter Suspends Dividend As Part Of Capital Allocation Reprioritization

Michigan Beats California In Legal Cannabis Sales: Why Is Golden State’s Weed Industry Losing Its Shine?

HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

Here’s Why Rivian (RIVN) Stock Is Rising